| All Releases |
|---|
 |
Osiris Announces Second Quarter Results; Osteocel(R) Sales Growth Exceeds 50% for the 4th Consecutive Quarter
09-12-06
17.3 KB
|
| |
BALTIMORE, Sep 12, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its financial results for the second quarter and six months ended June 30, 2006...
|
|
Osiris Announces Second Quarter 2006 Financial Results Conference Call
09-08-06
9.2 KB
|
| |
BALTIMORE, Sep 08, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas will report its financial results for the second quarter ended June 30, 2006, after the close o...
|
|
Osiris Announces Expansion of Board of Directors and Key Additions to its Senior Management Team
08-14-06
8.7 KB
|
| |
August 14, 2006 – Baltimore, MD – With the successful closing of our initial public offering, Osiris Therapeutics Inc. (NasdaqGM:OSIR) is pleased to announce the election of Jay M. Moyes and Gregory H. Barnhill to the Board of Directors. We are also pleased to announce the addition of Earl R. Fender and Lode Debrabandere, Ph.D. to o...
|
|
Osiris Announces Pricing of Its Initial Public Offering
08-04-06
8.2 KB
|
| |
August 4, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a price of $11.00 per share. All of the shares are being sold by the Company. Up to an additional 525,000 shares have been made available to the underwriters to cover over-allotm...
|
|
Osiris Updates Information on Initial Public Offering
07-17-06
8.5 KB
|
| |
July 17, 2006 - Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that it filed an amendment to the registration statement for its previously announced initial public offering reflecting its intention to offer 3,500,000 shares of its common stock at $11.00 to $13.00 per share. Up to an additional 525,000 shares are expected to ...
|
|
Osiris Files for Initial Public Offering
05-12-06
9.0 KB
|
| |
May 12, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that the Company has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been de...
|
|
Osiris Completes Enrollment in Stem Cell Trial for Knee Repair
04-25-06
10.9 KB
|
| |
April 25, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that it has completed enrollment in the first human clinical trial of a stem cell therapy to repair tissue in the knee. A total of 55 patients were treated in the Phase I/II double blinded, placebo-controlled trial designed to evaluate the safety and effectiven...
|
|
Osiris Completes Enrollment in Stem Cell Trial to Treat Cardiac Disease
04-05-06
11.1 KB
|
| |
April 5, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today that it has completed enrollment in a human clinical trial designed to evaluate the safety and preliminary effectiveness of its universal adult stem cell drug candidate Provacel™, being developed to treat patients suffering from heart attacks. A total of 53 pat...
|
|
Osiris Stem Cell Funding Totals $70 Million for 2005
12-21-05
11.0 KB
|
| |
BALTIMORE, Maryland - December 21, 2005 - Osiris Therapeutics, Inc. announced that it has closed a $19 million private equity round. The money will fund the company’s five ongoing clinical trial programs using their proprietary adult stem cell technology platform. The round was arranged by Swiss investment firm Friedli Corporate Finance, In...
|
|
Osiris Receives Orphan Drug Status from FDA for Lead Stem Cell Drug
12-20-05
9.3 KB
|
| |
BALTIMORE, Maryland – December 20, 2005 - Osiris Therapeutics, Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for PROCHYMAL™, an adult stem cell product under investigation for the treatment of acute Graft vs. Host Disease (GVHD). Orphan drug status provides market exclusiv...
|
|
